Hims & Hers Health Inc. (HIMS)

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

With the way negative stock market sentiment  has piled up recently, short squeezes have generated some massive returns.

Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.

Hims & Hers Health's acquisition of ZAVA fast-tracks its entry into Europe's weight-loss market, expanding its subscriber base by 54%. The deal is attractively priced, non-dilutive, and leverages ZAVA...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.

Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in...

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (HIMS 6.96%) may finally be succeeding in cracking the code.

When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in artificial intelligence (AI). Sure, stocks such as Palantir Techno...